Companion diagnostics need to evolve from predicting a patient’s response to one specific drug to tests that predict their response to many different drugs.

Kinomica is developing mass spectrometry-based diagnostics that can reveal the actual activity, rather than just the presence, of the many hundreds of proteins we use as biomarkers.

This is set to transform precision medicine by enabling diagnostic tests that are highly predictive of how a patient will respond to a range of different therapeutic options, substantially aiding and improving the medical decision-making process.


companion diagnostics match the drug to the right patients


multi-drug diagnosticsmatch the patients to the right drug

We are initially developing diagnostic tests that
predict how a patient will respond to front-line therapies
for the following diseases.

Hepatocellular Carcinoma

The most common type of primary liver cancer, which is the fourth most prevalent cancer globally and the third highest cause of cancer deaths. Hepatocellular carcinoma has a 5-year survival rate below 15%.

Acute Myeloid Leukaemia

The second most common type of leukemia making up a third of cases. It has a 5-year survival rate below 25%.